<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postinduction therapy for peripheral T cell lymphoma (excluding systemic anaplastic large cell lymphoma) in transplant-eligible patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postinduction therapy for peripheral T cell lymphoma (excluding systemic anaplastic large cell lymphoma) in transplant-eligible patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Postinduction therapy for peripheral T cell lymphoma (excluding systemic anaplastic large cell lymphoma) in transplant-eligible patients</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm describes postinduction management of PTCL in adults, excluding sALCL. Refer to related UpToDate material for details of diagnosis, staging, prognosis, treatment, eligibility for HCT, and response assessment. Management of relapsed/refractory PTCL is discussed separately.</div><div class="graphic_footnotes"><p>CR: complete response; HCT: hematopoietic cell transplantation; IPI: international prognostic index; PET: positron emission tomography; PET3: PET after 3 cycles of induction therapy; PIT: prognostic index for PTCL; PR: partial response; PTCL: peripheral T cell lymphoma; sALCL: systemic anaplastic large cell lymphoma.</p>
<p>* Based on disease stage and IPI or PIT score at diagnosis.</p>
<p>¶ Based on 5-point (Deauville) score using Lugano criteria and compared with PET3.</p>
<p>Δ A single site of persistent disease amenable to radiation therapy.</p>
◊ The choice of observation versus autologous HCT must be individualized.</div><div id="graphicVersion">Graphic 142873 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
